AUSTIN, Texas, Nov. 9, 2020 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will
host a conference call on Friday, November
13, at 8:30 a.m. Eastern time
to discuss its financial and operating results for the third
quarter 2020, in addition to providing a business update.
Event: VolitionRx Limited Third Quarter 2020 Earnings and
Business Update Conference Call
Date: Friday, November 13,
2020
Time: 8:30 a.m. Eastern
time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13713126
Cameron Reynolds, President and
Chief Executive Officer of Volition, will host the call along with
David Vanston, Chief Financial
Officer and Scott Powell, Executive
Vice President, Investor Relations. The call will provide an update
on recent developments and Volition's activities, including details
of new and ongoing clinical trials, important events which have
taken place in the third quarter of 2020, and milestones for
remainder of 2020 and beyond.
A live audio webcast of the conference call will also be
available on the investor relations page of Volition's corporate
website at http://ir.volition.com. In addition, a telephone replay
of the call will be available until November
27, 2020. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13713126.
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of NucleosomicsTM, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily
focused on human diagnostics but also has a subsidiary focused on
animal diagnostics.
Volition's research and development activities are centered in
Belgium, with additional offices
in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
NucleosomicsTM is a trademark of Volition and its
subsidiaries.
For more information about Volition, visit Volition's website
(http://www.volition.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Pegasus
jen.lewis@thisispegasus.co.uk
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
View original
content:http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2020-earnings-conference-call-and-business-update-301168523.html
SOURCE VolitionRx Ltd